• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奥密克戎变异株导致嗅觉功能障碍的流行情况:一项系统评价和荟萃分析。

Prevalence of Olfactory Dysfunction with the Omicron Variant of SARS-CoV-2: A Systematic Review and Meta-Analysis.

机构信息

Department of Physiology and Cell Biology, Reno School of Medicine, University of Nevada, Reno, NV 89557-0352, USA.

School of Public Health, University of Nevada, Reno, NV 89557-0275, USA.

出版信息

Cells. 2023 Jan 28;12(3):430. doi: 10.3390/cells12030430.

DOI:10.3390/cells12030430
PMID:36766771
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9913864/
Abstract

The omicron variant is thought to cause less olfactory dysfunction than previous variants of SARS-CoV-2, but the reported prevalence differs greatly between populations and studies. Our systematic review and meta-analysis provide information regarding regional differences in prevalence as well as an estimate of the global prevalence of olfactory dysfunction based on 62 studies reporting information on 626,035 patients infected with the omicron variant. Our estimate of the omicron-induced prevalence of olfactory dysfunction in populations of European ancestry is 11.7%, while it is significantly lower in all other populations, ranging between 1.9% and 4.9%. When ethnic differences and population sizes are considered, the global prevalence of omicron-induced olfactory dysfunction in adults is estimated to be 3.7%. Omicron's effect on olfaction is twofold to tenfold lower than that of the alpha or delta variants according to previous meta-analyses and our analysis of studies that directly compared the prevalence of olfactory dysfunction between omicron and previous variants. The profile of the prevalence differences between ethnicities mirrors the results of a recent genome-wide association study that connected a gene locus encoding an odorant-metabolizing enzyme, UDP glycosyltransferase, to the extent of COVID-19-related loss of smell. Our analysis is consistent with the hypothesis that this enzyme contributes to the observed population differences.

摘要

奥密克戎变异株被认为比以前的 SARS-CoV-2 变异株引起的嗅觉障碍少,但报告的流行率在不同人群和研究中差异很大。我们的系统评价和荟萃分析提供了关于流行率的区域差异的信息,以及根据 62 项报告有关感染奥密克戎变异株的 626,035 名患者信息的研究,估计全球嗅觉障碍流行率的信息。我们对欧洲血统人群中奥密克戎引起的嗅觉障碍流行率的估计为 11.7%,而在所有其他人群中,这一比例显著较低,在 1.9%至 4.9%之间。当考虑到种族差异和人口规模时,估计全球成年人中奥密克戎引起的嗅觉障碍的流行率为 3.7%。根据之前的荟萃分析和我们对直接比较奥密克戎和以前变异株引起的嗅觉障碍流行率的研究的分析,奥密克戎对嗅觉的影响比阿尔法或德尔塔变异株低两到十倍。种族间流行率差异的特征与最近一项全基因组关联研究的结果相吻合,该研究将编码一种气味代谢酶的基因座与 COVID-19 相关嗅觉丧失的程度联系起来。我们的分析与假设一致,即这种酶有助于解释观察到的人群差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a9/9913864/181cce587806/cells-12-00430-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a9/9913864/13888a81c533/cells-12-00430-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a9/9913864/e171903af9fe/cells-12-00430-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a9/9913864/5334c43e99ad/cells-12-00430-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a9/9913864/1cc6d95ee9c6/cells-12-00430-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a9/9913864/27044b53475d/cells-12-00430-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a9/9913864/94ee310b8329/cells-12-00430-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a9/9913864/d10af33369b9/cells-12-00430-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a9/9913864/181cce587806/cells-12-00430-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a9/9913864/13888a81c533/cells-12-00430-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a9/9913864/e171903af9fe/cells-12-00430-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a9/9913864/5334c43e99ad/cells-12-00430-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a9/9913864/1cc6d95ee9c6/cells-12-00430-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a9/9913864/27044b53475d/cells-12-00430-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a9/9913864/94ee310b8329/cells-12-00430-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a9/9913864/d10af33369b9/cells-12-00430-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a9/9913864/181cce587806/cells-12-00430-g008.jpg

相似文献

1
Prevalence of Olfactory Dysfunction with the Omicron Variant of SARS-CoV-2: A Systematic Review and Meta-Analysis.奥密克戎变异株导致嗅觉功能障碍的流行情况:一项系统评价和荟萃分析。
Cells. 2023 Jan 28;12(3):430. doi: 10.3390/cells12030430.
2
Prevalence of Olfactory Dysfunction with the Omicron Variant of SARS-CoV-2: A Systematic Review and Meta-analysis.新型冠状病毒奥密克戎变异株导致嗅觉功能障碍的患病率:一项系统评价和荟萃分析
medRxiv. 2023 Jan 19:2022.12.16.22283582. doi: 10.1101/2022.12.16.22283582.
3
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
4
Pathophysiological relationship between COVID-19 and olfactory dysfunction: A systematic review.新型冠状病毒肺炎与嗅觉功能障碍的病理生理学关系:系统综述。
Braz J Otorhinolaryngol. 2022 Sep-Oct;88(5):794-802. doi: 10.1016/j.bjorl.2021.04.001. Epub 2021 Apr 25.
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
6
Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction.预防持续性 COVID-19 后嗅觉功能障碍的干预措施。
Cochrane Database Syst Rev. 2022 Sep 5;9(9):CD013877. doi: 10.1002/14651858.CD013877.pub3.
7
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦/利托那韦片用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD015395. doi: 10.1002/14651858.CD015395.pub3.
8
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.SARS-CoV-2 中和单克隆抗体预防 COVID-19。
Cochrane Database Syst Rev. 2022 Jun 17;6(6):CD014945. doi: 10.1002/14651858.CD014945.pub2.
9
Long-COVID Symptoms in Individuals Infected with Different SARS-CoV-2 Variants of Concern: A Systematic Review of the Literature.不同关注的 SARS-CoV-2 变异株感染个体的长新冠症状:文献系统综述。
Viruses. 2022 Nov 25;14(12):2629. doi: 10.3390/v14122629.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.

引用本文的文献

1
Omicron Impacts Olfaction in Hamsters.奥密克戎对仓鼠嗅觉的影响。
FASEB J. 2025 Jul 31;39(14):e70879. doi: 10.1096/fj.202501431RR.
2
Olfactory impairment associated with reduced physical capacity 24 months after COVID-19.新冠病毒感染24个月后嗅觉障碍与身体机能下降相关
Brain Behav Immun Health. 2025 Jun 13;47:101032. doi: 10.1016/j.bbih.2025.101032. eCollection 2025 Aug.
3
Insight into NeuroCOVID: neurofilament light chain (NfL) as a biomarker in post-COVID-19 patients with olfactory dysfunctions.深入了解神经新冠:神经丝轻链(NfL)作为新冠后嗅觉功能障碍患者的生物标志物

本文引用的文献

1
Course and clinical severity of the SARS-CoV-2 Omicron variant infection in Tianjin, China.中国天津地区 SARS-CoV-2 奥密克戎变异株感染的病程和临床严重程度。
Medicine (Baltimore). 2023 Sep 22;102(38):e34669. doi: 10.1097/MD.0000000000034669.
2
Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected With Omicron Subvariants and the XBB Recombinant Variant.感染奥密克戎亚变体和XBB重组变体的实验室确诊新冠病毒病例的临床特征与转归
Cureus. 2023 Feb 21;15(2):e35261. doi: 10.7759/cureus.35261. eCollection 2023 Feb.
3
Comparison of Clinical Presentation and Vaccine Effectiveness Among Omicron and Non-omicron SARS Coronavirus-2 Patients.
J Neurol. 2025 Jul 1;272(7):484. doi: 10.1007/s00415-025-13222-w.
4
Receptor Binding for the Entry Mechanisms of SARS-CoV-2: Insights from the Original Strain and Emerging Variants.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)进入机制的受体结合:来自原始毒株和新出现变体的见解
Viruses. 2025 May 10;17(5):691. doi: 10.3390/v17050691.
5
Towards universal chemosensory testing: needs, barriers, and opportunities.迈向通用化学感应测试:需求、障碍与机遇。
Chem Senses. 2025 Jan 22;50. doi: 10.1093/chemse/bjaf015.
6
Identifying COVID-19 variant through symptoms profile: Would it be possible? A rapid review.通过症状特征识别 COVID-19 变异株:这是否可行?快速综述。
BMC Infect Dis. 2024 Nov 14;24(1):1306. doi: 10.1186/s12879-024-10094-9.
7
Insights into Molecular and Cellular Mechanisms of NeuroCOVID.神经 COVID 的分子和细胞机制研究进展。
Cells. 2024 Oct 29;13(21):1790. doi: 10.3390/cells13211790.
8
Clinical presentations, systemic inflammation response and ANDC scores in hospitalized patients with COVID-19.COVID-19 住院患者的临床表现、全身炎症反应和 ANDC 评分。
Sci Rep. 2024 Sep 28;14(1):22480. doi: 10.1038/s41598-024-73001-x.
9
Polyunsaturated Fatty Acids as Potential Treatments for COVID-19-Induced Anosmia.多不饱和脂肪酸作为新冠病毒感染所致嗅觉丧失的潜在治疗方法
Biomedicines. 2024 Sep 12;12(9):2085. doi: 10.3390/biomedicines12092085.
10
Factors Associated With Persisting Olfactory Dysfunction After COVID-19.新冠病毒感染后持续性嗅觉功能障碍的相关因素
Clin Otolaryngol. 2025 Jan;50(1):53-61. doi: 10.1111/coa.14233. Epub 2024 Sep 21.
奥密克戎和非奥密克戎型严重急性呼吸综合征冠状病毒2患者的临床表现及疫苗有效性比较。
Cureus. 2022 Dec 9;14(12):e32354. doi: 10.7759/cureus.32354. eCollection 2022 Dec.
4
Comparative study of clinical features and vaccination status in Omicron and non-Omicron infected patients during the third wave in Mumbai, India.印度孟买第三波疫情期间奥密克戎毒株感染患者与非奥密克戎毒株感染患者的临床特征及疫苗接种状况比较研究
J Family Med Prim Care. 2022 Oct;11(10):6135-6142. doi: 10.4103/jfmpc.jfmpc_430_22. Epub 2022 Oct 31.
5
Pathophysiology of SARS-CoV-2 Infection of Nasal Respiratory and Olfactory Epithelia and Its Clinical Impact.SARS-CoV-2 感染鼻腔呼吸道和嗅觉上皮的病理生理学及其临床影响。
Curr Allergy Asthma Rep. 2023 Feb;23(2):121-131. doi: 10.1007/s11882-022-01059-6. Epub 2023 Jan 4.
6
Clinical characteristics of patients infected with novel coronavirus wild strain, Delta variant strain and Omicron variant strain in Quanzhou: A real‑world study.泉州新型冠状病毒野生株、德尔塔变异株及奥密克戎变异株感染患者的临床特征:一项真实世界研究
Exp Ther Med. 2022 Dec 9;25(1):62. doi: 10.3892/etm.2022.11761. eCollection 2023 Jan.
7
COVID-19 Symptoms by Variant Period in the North Carolina COVID-19 Community Research Partnership, North Carolina, USA.美国北卡罗来纳州 COVID-19 社区研究合作组织中,不同变异株流行时期的 COVID-19 症状。
Emerg Infect Dis. 2023 Jan;29(1):207-211. doi: 10.3201/eid2901.221111.
8
The impact of variant and vaccination on SARS-CoV-2 symptomatology; three prospective household cohorts.变异株和疫苗接种对 SARS-CoV-2 症状学的影响:三项前瞻性家庭队列研究。
Int J Infect Dis. 2023 Mar;128:140-147. doi: 10.1016/j.ijid.2022.12.018. Epub 2022 Dec 23.
9
SARS-CoV-2 infection among healthcare workers whom already received booster vaccination during epidemic outbreak of omicron variant in Taiwan.台湾奥密克戎变异株流行期间,已接种加强针的医护人员中的 SARS-CoV-2 感染。
J Formos Med Assoc. 2023 May;122(5):376-383. doi: 10.1016/j.jfma.2022.12.003. Epub 2022 Dec 16.
10
Persistent post-COVID-19 smell loss is associated with immune cell infiltration and altered gene expression in olfactory epithelium.持续性新冠后嗅觉丧失与嗅上皮免疫细胞浸润和基因表达改变有关。
Sci Transl Med. 2022 Dec 21;14(676):eadd0484. doi: 10.1126/scitranslmed.add0484.